Paul Bălănescu1,2,3, Anca Lădaru4, Eugenia Bălănescu5, Theodor Voiosu6,7, Cristian Băicuş6,7,8, Gheorghe Andrei Dan6,7,8. 1. CDPC Clinical Immunology Department, Colentina Clinical Hospital, Bucharest, Romania. plbalanescu@gmail.com. 2. Internal Medicine Chair, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania. plbalanescu@gmail.com. 3. Clinical Research Unit, RECIF (Réseau d' Epidémiologie Clinique International Francophone), Bucharest, Romania. plbalanescu@gmail.com. 4. Pediatrics Department, Institute for Mother and Child Protection "Alfred Rusescu," Bucharest, Romania. 5. CDPC Clinical Immunology Department, Colentina Clinical Hospital, Bucharest, Romania. 6. Internal Medicine Chair, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania. 7. Clinical Research Unit, RECIF (Réseau d' Epidémiologie Clinique International Francophone), Bucharest, Romania. 8. Department of Internal Medicine, Colentina Clinical Hospital, Bucharest, Romania.
Abstract
BACKGROUND: Systemic sclerosis (Ssc) is an autoimmune disease characterized by vascular alterations of small arteries and microvessels with subsequent tissue fibrosis. Endocan is expressed by endothelial cells and associated with endothelial dysfunction; therefore it could be a potential biomarker for Ssc patients. METHODS: Twenty-one Ssc patients and 20 sex- and age-matched healthy controls were recruited for the study. Serum endocan levels were determined using ELISA method in all patients and controls. RESULTS: Serum endocan levels were superior in Ssc patients (median 2.53 (1.10-7 ng/ml)) compared with controls (0.79 (0-2 ng/ml), P < 0.05). Higher serum endocan expression was seen in diffuse Ssc subset and associated with the presence of digital ulcers and daily Raynaud's phenomenon (P < 0.05). Higher serum endocan levels were associated with a modified Rodnan skin score >14 and longer disease duration (P < 0.05). Values of areas under the receiver operating curves showed that serum endocan had good discriminative power for Ssc diagnosis, differentiating diffuse from limited subset type and differentiating patients with modified Rodnan skin score above and under 14 (area under curve: 0.94, 0.81, 0.75, respectively). CONCLUSION: The results of this pilot study suggest endocan as a potential biomarker for microvascular manifestations and complications in Ssc patients. These encouraging results could promote future prospective studies in order to determine the exact role played by endocan as a biomarker for Ssc.
BACKGROUND: Systemic sclerosis (Ssc) is an autoimmune disease characterized by vascular alterations of small arteries and microvessels with subsequent tissue fibrosis. Endocan is expressed by endothelial cells and associated with endothelial dysfunction; therefore it could be a potential biomarker for Ssc patients. METHODS: Twenty-one Ssc patients and 20 sex- and age-matched healthy controls were recruited for the study. Serum endocan levels were determined using ELISA method in all patients and controls. RESULTS: Serum endocan levels were superior in Ssc patients (median 2.53 (1.10-7 ng/ml)) compared with controls (0.79 (0-2 ng/ml), P < 0.05). Higher serum endocan expression was seen in diffuse Ssc subset and associated with the presence of digital ulcers and daily Raynaud's phenomenon (P < 0.05). Higher serum endocan levels were associated with a modified Rodnan skin score >14 and longer disease duration (P < 0.05). Values of areas under the receiver operating curves showed that serum endocan had good discriminative power for Ssc diagnosis, differentiating diffuse from limited subset type and differentiating patients with modified Rodnan skin score above and under 14 (area under curve: 0.94, 0.81, 0.75, respectively). CONCLUSION: The results of this pilot study suggest endocan as a potential biomarker for microvascular manifestations and complications in Ssc patients. These encouraging results could promote future prospective studies in order to determine the exact role played by endocan as a biomarker for Ssc.
Authors: Dunja M Mihajlovic; Dajana F Lendak; Snezana V Brkic; Biljana G Draskovic; Gorana P Mitic; Aleksandra S Novakov Mikic; Tatjana N Cebovic Journal: Microvasc Res Date: 2014-04-21 Impact factor: 3.514
Authors: Paul Bălănescu; Anca Lădaru; Eugenia Bălănescu; Cristian Băicuş; Gheorghe Andrei Dan Journal: Biomarkers Date: 2014-05-16 Impact factor: 2.658
Authors: Mahmut I Yilmaz; Dimitrie Siriopol; Mutlu Saglam; Yasemin G Kurt; Hilmi U Unal; Tayfun Eyileten; Mahmut Gok; Hakki Cetinkaya; Yusuf Oguz; Sebahattin Sari; Abdulgaffar Vural; Irina Mititiuc; Adrian Covic; Mehmet Kanbay Journal: Kidney Int Date: 2014-07-02 Impact factor: 10.612
Authors: Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau Journal: Eur Heart J Date: 2009-08-27 Impact factor: 29.983
Authors: Yunliang Chen; Andrew Leask; David J Abraham; Daphne Pala; Xu Shiwen; Korsa Khan; Shangxi Liu; David E Carter; Sarah Wilcox-Adelman; Paul Goetinck; Christopher P Denton; Carol M Black; Andrew A Pitsillides; Catherine E Sarraf; Mark Eastwood Journal: Arthritis Rheum Date: 2008-02
Authors: P Clements; P Lachenbruch; J Siebold; B White; S Weiner; R Martin; A Weinstein; M Weisman; M Mayes; D Collier Journal: J Rheumatol Date: 1995-07 Impact factor: 4.666
Authors: Ahmet Omma; Berkan Armaǧan; Serdar Can Güven; Sevinç Can Sandıkçı; Seda Çolak; Çiǧdem Yücel; Orhan Küçükşahin; Abdulsamet Erden Journal: Front Pediatr Date: 2021-11-29 Impact factor: 3.418